Prostate Cancer Clinical Trial
Stereotactic Magnetic Resonance Guided Radiation Therapy
Summary
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.
Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Full Description
This research study is a feasibility study, which means it is the first-time investigators at this institution are examining this type of MR-guided radiation to treat cancer.
The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option for cancer.
In this research study, the investigators are hoping to determine if adjusting radiation treatments based on daily MRI has a feasible way to deliver radiation for participants with pancreatic, lung or renal cancer.
Eligibility Criteria
Inclusion Criteria:
Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
Tumor size ≤ 7cm
Age 18 years of older.
ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
Ability to understand and the willingness to sign a written informed consent document.
Specific eligibility requirements for each disease site with be covered in each specific cohort.
Exclusion Criteria:
Specific exclusion requirements for each disease site with be covered in each specific cohort
History of allergic reactions attributed to gadolinium-based IV contrast.
-- Note: If a patient will not receive contrast, this is not applicable
Pregnant women are excluded from this study.
Severe claustrophobia or anxiety
Participants who cannot undergo an MRI
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Boston Massachusetts, 02115, United States
Boston Massachusetts, 02115, United States
How clear is this clinincal trial information?